Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Allopurinol

FDA-approved product (tablet, oral), marketed as Allopurinol, Lopurin, Zyloprim and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Allopurinol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Gout
  • Leukemia
  • Lymphoma
  • Response Evaluation Criteria in Solid Tumors

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Preparations inhibiting uric acid production
FDA pharmacologic class
Xanthine Oxidase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Allopurinol, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA19.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis2.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 1 lab record
Open Allopurinol in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Allopurinol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antenatal Allopurinol in Intrauterine Growth Restriction

    NCT00346463 · start 2006-07

    Registered record
    Registry ID
    NCT00346463
    Conditions
    Fetal Growth Retardation
    Interventions
    Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2006-07
    Completion
    2013-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFetal Growth Retardation
    InterventionAllopurinol
    PhaseNot applicable
    Registry statusUnknown

  • An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

    NCT00823199 · start 2005-11

    Registered record
    Registry ID
    NCT00823199
    Conditions
    Schizophrenia
    Interventions
    Allopurinal
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-11
    Completion
    2008-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAllopurinal
    PhaseNot applicable
    Registry statusCompleted

  • Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

    NCT00061945 · start 2003-06

    Registered record
    Registry ID
    NCT00061945
    Conditions
    Acute Undifferentiated Leukemia; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; L1 Adult Acute Lymphoblastic Leukemia; L1 Childhood Acute Lymphoblastic Leukemia; L2 Adult Acute Lymphoblastic Leukemia; L2 Childhood Acute Lymphoblastic Leukemia; Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions
    allopurinol; cyclophosphamide; daunorubicin hydrochloride; vincristine sulfate; dexamethasone; asparaginase; filgrastim; imatinib mesylate; methotrexate; cytarabine; trimethoprim-sulfamethoxazole; mercaptopurine; leucovorin calcium; alemtuzumab; acyclovir; laboratory biomarker analysis; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2003-06
    Completion
    2012-10
    Enrolment
    302

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Undifferentiated Leukemia; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; L1 Adult Acute Lymphoblastic Leukemia +10 more
    Interventionallopurinol; cyclophosphamide; daunorubicin hydrochloride; vincristine sulfate +13 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

    NCT00039130 · start 2002-05

    Registered record
    Registry ID
    NCT00039130
    Conditions
    Leukemia; Lymphoma
    Interventions
    filgrastim; rituximab; cyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride; etoposide; ifosfamide; leucovorin calcium; methotrexate; prednisone; vincristine sulfate; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-05
    Completion
    2014-10
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    Interventionfilgrastim; rituximab; cyclophosphamide; cytarabine +9 more
    PhasePhase 2
    Registry statusCompleted

  • Vascular Pathophysiology in Obstructive Sleep Apnea

    NCT00214084

    Registered record
    Registry ID
    NCT00214084
    Conditions
    Obstructive Sleep Apnea
    Interventions
    Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea
    InterventionAllopurinol
    PhaseNot applicable
    Registry statusWithdrawn